摘要
【目的】观察醒脑解郁胶囊治疗伴躯体形式障碍的脑卒中后抑郁症患者的临床疗效。【方法】将60例伴躯体形式障碍的脑卒中后抑郁患者随机分为治疗组30例和对照组30例,在神经内科常规治疗的基础上,治疗组给予醒脑解郁胶囊(主要由石菖蒲、远志、郁金、柴胡、合欢皮、巴戟天、丹参等组成)联合黛力新治疗,对照组给予黛力新治疗,2组疗程均为8周。在第2、4、8周分别对2组患者进行汉密尔顿抑郁量表(HAMD)、抑郁自评量表(SDS)、症状自测量表(SDL-90)评分。【结果】(1)治疗后2组患者的HAMD分值均下降。治疗组自第2周开始与治疗前比较差异有非常显著性意义(P<0.01),对照组从第4周开始与治疗前比较差异有非常显著性意义(P<0.01)。治疗后组间比较,在第2周时差异有显著性意义(P<0.05)。(2)治疗后2组患者的SDS分值均下降。治疗组自第2周开始与治疗前比较差异有显著性意义(P<0.05),至第4周和第8周,差异有非常显著性意义(P<0.01);对照组从第4周开始与治疗前比较差异有显著性意义(P<0.05),至第8周,差异有非常显著性意义(P<0.01)。治疗后组间比较,在第2周和第4周时差异有显著性意义(P<0.05)。(3)2组治疗前后SDL-90评分的差值比较结果表明:治疗组在改善躯体症状、缓解抑郁症状方面的作用显著优于对照组(P<0.05或P<0.01)。【结论】醒脑解郁胶囊可明显改善脑卒中后抑郁症的躯体症状。
Objective To observe the therapeutic effect of Xingnao Jieyu Capsules（XJC） for post-stroke depression patients accompanied by somatoform disorders.Methods Sixty post-stroke depression patients accompanied by somatoform disorders were equally randomized into two groups.The treatment group was treated with XJC（mainly composed of Rhizoma Acori Tatarinowii,Radix Bupleuri,Cortex Albiziae,Radix Morindae Officinalis,and Radix Salviae Miltiorrhizae） and Deanxit on the basis of routine neurological treatment.The control group was given Deanxit based on routine treatment.The treatment course of the two groups lasted 8 weeks.Hamilton rating scale for depression（HAMD）,self-rating depressive scale（SDS）and symptom checklist-90（SCL-90） were used to evaluate the therapeutic effect in the two groups at week 2,4 and 8.Results （1） The HAMD score was decreased in the two groups after treatment.In the treatment group,HAMD score at week 2,4 and 8 differed from that before treatment（P0.01）.In the control group,HAMD score at week 4 and 8 differed from that before treatment（P0.01）.The difference of HAMD score was significant between the two groups at week 2（P0.05）.（2） SDS score was decreased in both groups after treatment,the difference was significant in the treatment group at week 2,4 and 8,and in the control group at week 4 and 8（P0.05 or P0.01 compared with that before treatment）.The difference of SDS score was obviously significant in the treatment group at week 4 and 8,and in the control group at week 4 and 8（P0.05 or P0.01 compared with that before treatment）,and was significant between the two groups at week 2 and 4（P0.05）.（3） The results of SDL-90 scoring showed that the treatment group had better effect on relieving somatoform disorders and depression（P0.05 or P0.01）.Conclusion XJC exerts certain effect on relieving somatoform disorders in post-stroke depression patients.
出处
《广州中医药大学学报》
CAS
2011年第6期586-589,共4页
Journal of Guangzhou University of Traditional Chinese Medicine
基金
陕西省13115科技创新工程重大科技专项项目(编号:2010JDKG-65)
